Pharmaceuticals

Pharma By Matthew Herper

What we know — and don’t know — about Merck’s new Covid-19 pill

First Opinion By Howard S. Hochster

FDA’s naming rule for biosimilars has undermined Congress and health care

Biotech By Adam Feuerstein

The biotech scorecard for the fourth quarter: 19 stock-moving events to watch

Pharmalot By Ed Silverman

Pfizer loses a lawsuit alleging the U.S. illegally limits use of patient copay assistance programs

Pharmalot By Ed Silverman

Defense Department watchdog criticizes oversight of military’s pharmaceutical supply chain

Pharmalot By Ed Silverman

Compound pharmacies win court battle over an FDA plan for monitoring shipments

Pharmalot By Ed Silverman

Pharmalittle: J&J says its Covid-19 shot is more effective in two doses; India plans to resume Covid-19 vaccine exports

Pharmalot By Ed Silverman

Former Mylan IT exec pleads guilty to insider trading on earnings, drug approvals, and merger

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Casey Ross

Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal

Pharmalot By Ed Silverman

After a court let them off the hook, generic Zantac makers plan to seek legal expenses from consumers

Pharmalot By Ed Silverman

FDA commissioner, two senators raise concerns about patent abuse by pharmaceutical companies

Pharmalot By Ed Silverman

Cancer drug indications remain on labels even after trials fail to confirm their benefits

First Opinion By Alfred Engelberg

Outdated rule increases Medicare’s costs for generic drugs by $26 billion a year

Pharmalot By Ed Silverman

Older job seekers claim that Lilly favors millennials when it comes to hiring sales reps

Pharmalot By Ed Silverman

‘A step in the right direction for national security’: An antibiotic plant reopens in Tennessee to make penicillin

Politics By Nicholas Florko

FDA, drug makers propose new pilots aimed at speeding rare disease drugs, as part of user fee update

Pharmalot By Ed Silverman

After company protest, FDA agrees to review controversial drug to prevent premature birth

First Opinion By Michelle McMurry-Heath

Waiving intellectual property rights would compromise global vaccination efforts

Pharmalot By Ed Silverman

As use of widely prescribed stimulants increases, experts see troubling parallels to opioid crisis

First Opinion By Anthony Yanni

A ‘great listening’ to patients could be a powerful legacy of the pandemic

Health By Claudia López Lloreda

‘Stuck in a cul-de-sac’: Researchers are finally breaking away from the central dogma of depression

Health By Nicholas St. Fleur

STAT+ Conversation: Blueprint for cancer drugs

Pharmalot By Ed Silverman

U.K. antitrust watchdog issues a provisional ruling that Pfizer engaged in price gouging

Pharmalot By Ed Silverman

Most Read

For the first time, WHO committee recommends action on high-priced essential medicines

Pharma is showering Congress with cash, even as drug makers race to fight the coronavirus

Many hospitalized Covid-19 patients are given antibiotics. That’s a problem

Inflation and rebates caused wholesale prices on medicines to drop in second quarter

Failure to warn: Hundreds died while taking an arthritis drug, but nobody alerted patients

Drug used to halt puberty in children may cause lasting health problems

Anxious about a big speech? This startup wants to calm you down — with a cardiac drug you pop like a mint

Even me-too drugs matter when it comes to new medicines

All Coverage

What we know — and don’t know — about Merck’s new Covid-19 pill

FDA’s naming rule for biosimilars has undermined Congress and health care

The biotech scorecard for the fourth quarter: 19 stock-moving events to watch

Pfizer loses a lawsuit alleging the U.S. illegally limits use of patient copay assistance programs

Defense Department watchdog criticizes oversight of military’s pharmaceutical supply chain

Compound pharmacies win court battle over an FDA plan for monitoring shipments

Pharmalittle: J&J says its Covid-19 shot is more effective in two doses; India plans to resume Covid-19 vaccine exports

Former Mylan IT exec pleads guilty to insider trading on earnings, drug approvals, and merger

Up and down the ladder: The latest comings and goings

Pharmalittle: FDA scientists skeptical on boosters; moderate Democrats sink Pelosi’s drug pricing proposal

After a court let them off the hook, generic Zantac makers plan to seek legal expenses from consumers

FDA commissioner, two senators raise concerns about patent abuse by pharmaceutical companies

Cancer drug indications remain on labels even after trials fail to confirm their benefits

Outdated rule increases Medicare’s costs for generic drugs by $26 billion a year

Older job seekers claim that Lilly favors millennials when it comes to hiring sales reps

‘A step in the right direction for national security’: An antibiotic plant reopens in Tennessee to make penicillin

FDA, drug makers propose new pilots aimed at speeding rare disease drugs, as part of user fee update

After company protest, FDA agrees to review controversial drug to prevent premature birth

Waiving intellectual property rights would compromise global vaccination efforts

As use of widely prescribed stimulants increases, experts see troubling parallels to opioid crisis

A ‘great listening’ to patients could be a powerful legacy of the pandemic

‘Stuck in a cul-de-sac’: Researchers are finally breaking away from the central dogma of depression

STAT+ Conversation: Blueprint for cancer drugs

U.K. antitrust watchdog issues a provisional ruling that Pfizer engaged in price gouging

Bayer inks a $1.5 billion deal for a biotech with a proprietary drug discovery platform

pharmaceuticals

Most Read

All Coverage